Daily aspirin is significantly associated with a reduced risk for liver cancer in patients with hepatitis B virus (HBV), according to an analysis of data from a nationwide cohort study.
The findings, presented at the 2017 Liver Meeting (abstract 223), showed that aspirin cut the incidence of liver cancer from 5.59% to 2.86% in patients with HBV.
Investigator Teng-Yu Lee, MD, PhD, MBA, a researcher in the Department of Gastroenterology at Taichung Veterans General Hospital, in Taiwan, said the